Memantine: A Review of Its Use in Alzheimer’s Disease

Clinical diagnosis of Alzheimer's disease: Report of the NINCDS‐ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915 · see citing works

A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease

Sano, M., Ernesto, C., Thomas, R. G., Klauber, M. R., Schafer, K., Grundman, M., Woodbury, P., Growdon, J., Cotman, C. W., Pfeiffer, E., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704243361704 · Cited by 2,380 · see citing works

Memantine in Moderate-to-Severe Alzheimer's Disease

Reisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S., & Möbius, H. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa013128 · Cited by 2,043 · see citing works

Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment

Petersen, R. C., Thomas, R. G., Grundman, M., Bennett, D., Doody, R., Ferris, S., Galasko, D., Jin, S., Kaye, J., Levey, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050151 · Cited by 1,844 · see citing works

Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset.

Brookmeyer, R., Gray, S. G., & Kawas, C. H. (1998) · American Journal of Public Health · doi:10.2105/ajph.88.9.1337 · Cited by 1,774 · see citing works

Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported

Evans, D. A. (1989) · JAMA · doi:10.1001/jama.262.18.2551 · Cited by 1,627 · see citing works

Memantine Treatment in Patients With Moderate to Severe Alzheimer Disease Already Receiving Donepezil: A Randomized Controlled Trial

Tariot, P. N., Farlow, M. R., Grossberg, G. T., Graham, S. M., McDonald, S., Gergel, I., & for the Memantine Study Group (2004) · JAMA · doi:10.1001/jama.291.3.317 · Cited by 1,403 · see citing works

Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization

Orgogozo, J.-M., Gilman, S., Dartigues, J.-F., Laurent, B., Puel, M., Kirby, L. C., Jouanny, P., Dubois, B., Eisner, L., Flitman, S., et al. (2003) · Neurology · doi:10.1212/01.wnl.0000073623.84147.a8 · Cited by 1,356 · see citing works

Prevalence of Alzheimer's Disease in a Community Population of Older Persons: Higher Than Previously Reported

Evans, D. A. (1989) · JAMA · doi:10.1001/jama.1989.03430180093036 · Cited by 1,226 · see citing works

Alzheimer’s disease

Cummings, J. L. (2004) · New England Journal of Medicine · doi:10.1056/nejmra040223 · Cited by 1,152 · see citing works

Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society.

Small, G., Rabins, P., Barry, P. P., Buckholtz, N., Dekosky, S., Ferris, S., Finkel, S., Gwyther, L., Khachaturian, Z., Lebowitz, B., et al. (1997) · Journal of the American Medical Association (JAMA) · doi:10.1001/jama.1997.03550160083043 · Cited by 949 · see citing works

Memantine is a clinically well tolerated N-methyl-d-aspartate (NMDA) receptor antagonist—a review of preclinical data

Parsons, C. G., Danysz, W., & Quack, G. (1999) · Neuropharmacology · doi:10.1016/s0028-3908(99)00019-2 · Cited by 881 · see citing works

Donepezil Improves Cognition and Global Function in Alzheimer Disease A 15-Week, Double-blind, Placebo-Controlled Study

Rogers, S. L. (1998) · Archives of Internal Medicine · doi:10.1001/archinte.158.9.1021 · Cited by 770 · see citing works

Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity

Chen, H., Pellegrini, J. W., Aggarwal, S., Lei, S., Warach, S. J., Jensen, F., & Lipton, S. A. (1992) · Journal of Neuroscience · doi:10.1523/jneurosci.12-11-04427.1992 · Cited by 630 · see citing works

A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease

Feldman, H., Gauthier, S. G., Hecker, J., Vellas, B. J., Subbiah, P., Whalen, E., & the Donepezil MSAD Study Investigators Group* (2001) · Neurology · doi:10.1212/wnl.57.4.613 · Cited by 600 · see citing works

Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported.

Evans, D. A., Funkenstein, H. H., Albert, M., Scherr, P. A., Cook, N. R., Chown, M. J., Hebert, L. E., Hennekens, C. H., & Taylor, J. O. (1989) · PubMed · Cited by 599 · see citing works

Efficacy and Safety of Memantine in Patients With Mild to Moderate Vascular Dementia: A Randomized, Placebo-Controlled Trial (MMM 300)

Orgogozo, J.-M., Rigaud, A.-S., Stöffler, A., Möbius, H.-J., & Forette, F. (2002) · Stroke · doi:10.1161/01.str.0000020094.08790.49 · Cited by 539 · see citing works

The Magnitude of Dementia Occurrence in the World

Wimo, A. B., Winblad, B. G., Agüero‐Torres, H., & Strauss, E. I. V. (2003) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-200304000-00002 · Cited by 536 · see citing works

To: A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease

(2001) · Neurology · doi:10.1212/wnl.57.11.2153-a · Cited by 490 · see citing works

Screening for thrombophilia in high-risk situations: systematic review and cost-effectiveness analysis. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study

Wu, O., Robertson, L., Twaddle, S., Lowe, G. D. O., Clark, P., Greaves, M., Walker, I. D., Langhorne, P., Brenkel, I., Regan, L., et al. (2006) · Health Technology Assessment · doi:10.3310/hta10110 · Cited by 489 · see citing works

Age-Specific Incidence of Alzheimer's Disease in a Community Population

Hebert, L. E. (1995) · JAMA · doi:10.1001/jama.1995.03520410048025 · Cited by 462 · see citing works

The Neuropharmacological Basis for the Use of Memantine in the Treatment of Alzheimer's Disease

Rogawski, M. A., & Wenk, G. L. (2003) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2003.tb00254.x · Cited by 438 · see citing works

The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence

Danysz, W., & Parsons, C. G. (2003) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.938 · Cited by 404 · see citing works

A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500)

Wilcock, G., M??bius, H. J., & St??ffler, A. (2002) · International Clinical Psychopharmacology · doi:10.1097/00004850-200211000-00005 · Cited by 381 · see citing works

Memantine Treatment in Mild to Moderate Alzheimer Disease: A 24-Week Randomized, Controlled Trial

Peskind, E. R., Potkin, S. G., Pomara, N., Ott, B. R., Graham, S. M., Olin, J. T., & McDonald, S. (2006) · American Journal of Geriatric Psychiatry · doi:10.1097/01.jgp.0000224350.82719.83 · Cited by 307 · see citing works

Pharmacological Modulation of Perceptual Learning and Associated Cortical Reorganization

Dinse, H., Ragert, P., Pleger, B., Schwenkreis, P., & Tegenthoff, M. (2003) · Science · doi:10.1126/science.1085423 · Cited by 295 · see citing works

Patch clamp studies on the kinetics and selectivity of N-methyl-d-aspartate receptor antagonism by memantine (1-amino-3,5-dimethyladamantan)

Parsons, C. G., Gruner, R., Rozental, J., Millar, J. D., & Lodge, D. (1993) · Neuropharmacology · doi:10.1016/0028-3908(93)90029-3 · Cited by 279 · see citing works

Neuroprotection by memantine against neurodegeneration induced by β-amyloid(1–40)

Miguel-Hidalgo, J. J., Alvarez, X. A., Cacabelos, R., & Quack, G. (2002) · Brain Research · doi:10.1016/s0006-8993(02)03731-9 · Cited by 265 · see citing works

Trapping Channel Block of NMDA-Activated Responses By Amantadine and Memantine

Blanpied, T. A., Boeckman, F. A., Aizenman, E., & Johnson, J. W. (1997) · Journal of Neurophysiology · doi:10.1152/jn.1997.77.1.309 · Cited by 249 · see citing works

β-Amyloid-Stimulated Microglia Induce Neuron Death via Synergistic Stimulation of Tumor Necrosis Factor α and NMDA Receptors

Floden, A. M., Li, S., & Combs, C. K. (2005) · Journal of Neuroscience · doi:10.1523/jneurosci.4998-04.2005 · Cited by 246 · see citing works

Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment

Cummings, J. L., Schneider, E., Tariot, P. N., & Graham, S. M. (2006) · Neurology · doi:10.1212/01.wnl.0000223333.42368.f1 · Cited by 223 · see citing works

The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease

Loveman, E., Green, C., Kirby, J., Takeda, A., Picot, J., Payne, L., & Clegg, A. P. (2006) · Health Technology Assessment · doi:10.3310/hta10010 · Cited by 217 · see citing works

Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies

Gauthier, S. G., Wirth, Y., & Möbius, H. J. (2005) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1341 · Cited by 206 · see citing works

Neuroprotective concentrations of the N-methyl-D-aspartate open-channel blocker memantine are effective without cytoplasmic vacuolation following post-ischemic administration and do not block maze learning or long-term potentiation

Chen, H.-S. V., Wang, Y. F., Posina, V. R., Edgecomb, P., Neill, J. C., Segal, M. M., Lipton, S. A., & Jensen, F. E. (1998) · Neuroscience · doi:10.1016/s0306-4522(98)00163-8 · Cited by 202 · see citing works

The N-methyl-d-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl-cyclohexanes antagonise 5-HT3 receptor currents in cultured HEK-293 and N1E-115 cell systems in a non-competitive manner

Rammes, G., Rupprecht, R., Ferrari, U., Zieglgänsberger, W., & Parsons, C. G. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(01)01872-9 · Cited by 200 · see citing works

Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer’s disease and other neurologic disorders.

Lipton, S. A. (2005) · Journal of Alzheimer's Disease · doi:10.3233/jad-2004-6s610 · Cited by 194 · see citing works

Memantine Improves Spatial Learning in a Transgenic Mouse Model of Alzheimer’s Disease

Minkeviciene, R., Banerjee, P., & Tanila, H. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.071027 · Cited by 184 · see citing works

Influence of the N-methyl-d-aspartate antagonist memantine on human motor cortex excitability

Schwenkreis, P., Witscher, K., Janssen, F., Addo, A., Dertwinkel, R., Zenz, M. W., Malin, J.-P., & Tegenthoff, M. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(99)00492-9 · Cited by 182 · see citing works

A 24-Week Open-Label Extension Study of Memantine in Moderate to Severe Alzheimer Disease

Reisberg, ‌., Doody, R. S., Stöffler, A., Schmitt, F. A., Ferris, S. H., & Möbius, H. J. (2006) · Archives of Neurology · doi:10.1001/archneur.63.1.49 · Cited by 181 · see citing works

Guidelines for managing Alzheimer's disease: Part II. Treatment.

Cummings, J. L., Frank, J. C., Cherry, D., Kohatsu, N. D., Kemp, B. J., Hewett, L., & Mittman, B. S. (2002) · PubMed · Cited by 176 · see citing works

Resource Utilisation and Cost Analysis of Memantine in Patients with Moderate to Severe Alzheimer??s Disease

Wimo, A. B., Winblad, B. G., Stöffler, A., Wirth, Y., & Moebius, H. J. (2003) · PharmacoEconomics · doi:10.2165/00019053-200321050-00004 · Cited by 165 · see citing works

Neuroprotective effect of memantine demonstrated in vivo and in vitro

el Nasr, M. S., Peruche, B., Roβberg, C., Mennel, H.-D., & Krieglstein, J. (1990) · European Journal of Pharmacology · doi:10.1016/0014-2999(90)90206-l · Cited by 158 · see citing works

Cerebrospinal fluid and serum concentrations of the N-methyl-d-aspartate (NMDA) receptor antagonist memantine in man

Kornhuber, J., & Quack, G. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)11785-u · Cited by 155 · see citing works

The glutamatergic system and neurodegeneration in dementia: preventive strategies in Alzheimer's disease

Cacabelos, R., Takeda, M., & Winblad, B. G. (1999) · International Journal of Geriatric Psychiatry · doi:10.1002/(sici)1099-1166(199901)14:1 · Cited by 154 · see citing works

Memantine inhibits and reverses the Alzheimer type abnormal hyperphosphorylation of tau and associated neurodegeneration

Li, L., Sengupta, A., Haque, N., Grundke, I., & Iqbal, K. (2004) · FEBS Letters · doi:10.1016/j.febslet.2004.04.047 · Cited by 151 · see citing works

The Neuroprotective Agent Memantine Induces Brain-Derived Neurotrophic Factor and trkB Receptor Expression in Rat Brain

Marvanová, M., Lakso, M., Pirhonen, J., Nawa, H., Wong, G., & Ċastrén, E. (2001) · Molecular and Cellular Neuroscience · doi:10.1006/mcne.2001.1027 · Cited by 150 · see citing works

Non-Cholinergic Strategies for Treating and Preventing Alzheimer??s Disease

Doraiswamy, P. M. (2002) · CNS Drugs · doi:10.2165/00023210-200216120-00003 · Cited by 142 · see citing works

Pharmacokinetic study of memantine in healthy and renally impaired subjects

Periclou, A. P., Ventura, D., RAO, N., et al. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.10.005 · Cited by 107 · see citing works

Memantine is highly potent in protecting cortical cultures against excitotoxic cell death evoked by glutamate and N-methyl-D-aspartate

Erdö, S. L., & Schäfer, M. (1991) · European Journal of Pharmacology · doi:10.1016/0014-2999(91)90625-z · Cited by 105 · see citing works

Cost of Illness of Alzheimer's Disease: How Useful Are Current Estimates?

Bloom, B. S., de Pouvourville, N., & Straus, W. L. (2003) · The Gerontologist · doi:10.1093/geront/43.2.158 · Cited by 93 · see citing works

Delayed administration of memantine prevents N‐methyl‐ D ‐aspartate receptor‐mediated neurotoxicity

Pellegrini, J. W., & Lipton, S. A. (1993) · Annals of Neurology · doi:10.1002/ana.410330414 · Cited by 89 · see citing works

NMDA receptor antagonists. A new therapeutic approach for Alzheimer's disease.

Farlow, M. R. (2004) · PubMed · Cited by 86 · see citing works

No interaction of memantine with acetylcholinesterase inhibitors approved for clinical use

Wenk, G. L., Quack, G., Moebius, H. J., & Danysz, W. (2000) · Life Sciences · doi:10.1016/s0024-3205(00)00411-2 · Cited by 81 · see citing works

Neuroprotection of acetylcholinergic basal forebrain neurons by memantine and neurokinin B

Wenk, G. L., Zajaczkowski, W., & Danysz, W. (1997) · Behavioural Brain Research · doi:10.1016/s0166-4328(97)86056-1 · Cited by 81 · see citing works

Lack of Pharmacokinetic or Pharmacodynamic Interaction Between Memantine and Donepezil

Periclou, A. P., Ventura, D., Sherman, T., Rao, N. S., & Abramowitz, W. (2004) · Annals of Pharmacotherapy · doi:10.1345/aph.1d638 · Cited by 80 · see citing works

The Epidemic of Alzheimer??s Disease

Johnson, N., Davis, T., & Bosanquet, N. (2000) · PharmacoEconomics · doi:10.2165/00019053-200018030-00002 · Cited by 79 · see citing works

Drugs targeting alzheimer’s disease: Some things old and some things new

Michaelis, M. L. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.035840 · Cited by 78 · see citing works

NMDA receptor-mediated glutamate toxicity of cultured cerebellar, cortical and mesencephalic neurons: neuroprotective properties of amantadine and memantine

Weller, M., Finiels-Marlier, F., & Paul, S. M. (1993) · Brain Research · doi:10.1016/0006-8993(93)90464-x · Cited by 77 · see citing works

The NMDA antagonist memantine impairs classical eyeblink conditioning in humans

Schugens, M. M., Egerter, R., Daum, I., Schepelmann, K., Klockgether, T., & Löschmann, P. (1997) · Neuroscience Letters · doi:10.1016/s0304-3940(97)13452-8 · Cited by 64 · see citing works

Cost Effectiveness of Memantine in Alzheimer???s Disease

Jones, R. W., McCrone, P., & Guilhaume, C. (2004) · Drugs & Aging · doi:10.2165/00002512-200421090-00005 · Cited by 63 · see citing works

Management of Alzheimer's disease.

Grossberg, G., & Desai, A. (2003) · The journals of gerontology. Series A, Biological sciences and medical sciences · doi:10.1093/gerona/58.4.m331 · Cited by 60 · see citing works

Inhibitory effects of memantine on human cytochrome P450 activities: prediction of in vivo drug interactions

Mičuda, S., Mundlova, L., Anzenbacherová, E., et al. (2004) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-004-0825-1 · Cited by 56 · see citing works

The place of memantine in the treatment of Alzheimer's disease: a number needed to treat analysis

Livingston, G., & Katona, C. (2004) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1166 · Cited by 56 · see citing works

Effects of Pharmacologically Induced Changes in NMDA-Receptor Activity on Long-Term Memory in HumansPreprint

Rammsayer, T. H. (2001) · Learning & Memory · doi:10.1101/lm.33701 · Cited by 54 · see citing works

Memantine

Jarvis, B., & Figgitt, D. P. (2003) · Drugs & Aging · doi:10.2165/00002512-200320060-00005 · Cited by 54 · see citing works

Cost Effectiveness of Memantine in???Moderately Severe to Severe Alzheimer???s Disease

Fran??ois, C., Sintonen, H., Sulkava, R. O., & Rive, B. (2004) · Clinical Drug Investigation · doi:10.2165/00044011-200424070-00001 · Cited by 49 · see citing works

Cost-effectiveness of memantine for moderate to severe Alzheimer's disease in Sweden

Jönsson, L. (2005) · ˜The œAmerican journal of geriatric pharmacotherapy · doi:10.1016/j.amjopharm.2005.05.002 · Cited by 42 · see citing works

Apparent Independent Action of Nimodipine and Glutamate Antagonists to Protect Cultured Neurons Against Glutamate-induced Damage

Krieglstein, J., Lippert, K., & Pöch, G. (1996) · Neuropharmacology · doi:10.1016/s0028-3908(96)00104-9 · Cited by 41 · see citing works

Memantine enhances autonomy in moderate to severe Alzheimer's disease

Rive, B., Vercelletto, M., Delamarre-Damier, F., Cochran, J. M., & François, C. (2004) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1112 · Cited by 39 · see citing works

Memantine

Plosker, G. L., & Lyseng-Williamson, K. A. (2005) · PharmacoEconomics · doi:10.2165/00019053-200523020-00010 · Cited by 38 · see citing works

Distribution and Metabolism of the Potential Anti-Parkinson Drng Memantine in the Human

Wesemann, W., Sturm, G., & Fünfgeld, E. W. (1980) · Springer eBooks · doi:10.1007/978-3-7091-8582-7_15 · Cited by 37 · see citing works

Glutamate receptors as a target for Alzheimer’s disease — are clinical results supporting the hope?

Winblad, B. G., Möbius, H. J., & Stöffler, A. (2002) · Journal of neural transmission. Supplementum · doi:10.1007/978-3-7091-6139-5_20 · Cited by 33 · see citing works

New Approaches to Clinical Trials in Vascular Dementia: Memantine in Small Vessel Disease

Möbius, H. J., & Stöffler, A. (2002) · Cerebrovascular Diseases · doi:10.1159/000049153 · Cited by 33 · see citing works

The Use of Diurnal Vigilance Changes in the EEG to Verify Vigilance-Enhancing Effects of Memantine in a Clinical Pharmacological Study

Schulz, H., Jobert, M., Coppola, R., et al. (2008) · Neuropsychobiology · doi:10.1159/000119246 · Cited by 31 · see citing works

Treating the full spectrum of dementia with memantine

Winblad, B. G., & Jelić, V. (2003) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.937 · Cited by 26 · see citing works

Health Utilities in Alzheimer???s Disease and Implications for Cost-Effectiveness Analysis

Neumann, P. J. (2005) · PharmacoEconomics · doi:10.2165/00019053-200523060-00002 · Cited by 26 · see citing works

Memantine prevents progressive functional neurodegeneration in rats.

Heim, C. C., & Sontag, K. ‐. (1995) · PubMed · Cited by 23 · see citing works

A Systematic Review of the Clinical and Cost-Effectiveness of Memantine in Patients with Moderately Severe to Severe Alzheimer???s Disease

Kirby, J., Green, C., Loveman, E., et al. (2006) · Drugs & Aging · doi:10.2165/00002512-200623030-00005 · Cited by 22 · see citing works

Drug Development and Alzheimer Disease

Roses, A. D., & Pangalos, M. N. (2003) · American Journal of Geriatric Psychiatry · doi:10.1097/00019442-200303000-00003 · Cited by 16 · see citing works

Guidelines and Care Management Issues for People with Alzheimer??s Disease and Other Dementias

Maslow, K., Selstad, J., & Denman, S. J. (2002) · Disease Management & Health Outcomes · doi:10.2165/00115677-200210110-00003 · Cited by 13 · see citing works

Current drugs and future hopes in the treatment of Alzheimer’s disease

Windisch, M., Hutter‐Paier, B., & Schreiner, E. (2002) · Journal of neural transmission. Supplementum · doi:10.1007/978-3-7091-6139-5_15 · Cited by 12 · see citing works

Case Management Guideline

Smith, G. B. (2002) · Lippincott s Case Management · doi:10.1097/00129234-200203000-00005 · Cited by 3 · see citing works

Untitled work

Winblad (1999) · doi:10.1002/(sici)1099-1166(199902)14:2

Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies.

Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138 · see citing works

Drug treatments in Alzheimer’s disease

Briggs, R., Kennelly, S. P., & O’Neill, D. (2016) · Clinical Medicine · doi:10.7861/clinmedicine.16-3-247 · Cited by 571 · see citing works

N-methyl D-aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer’s disease, vascular dementia and Parkinson’s disease

Olivares, D., K. Deshpande, V., Shi, Y., K. Lahiri, D., H. Greig, N., T. Rogers, J., & Huang, X. (2012) · Current Alzheimer Research · doi:10.2174/156720512801322564 · Cited by 407 · see citing works

Role of Oxidative Damage in Alzheimer’s Disease and Neurodegeneration: From Pathogenic Mechanisms to Biomarker Discovery

Buccellato, F. R., D’Anca, M., Fenoglio, C., Scarpini, E., & Galimberti, D. (2021) · Antioxidants · doi:10.3390/antiox10091353 · Cited by 179 · see citing works

Alzheimer’s disease as type 3 diabetes: understanding the link and implications

Kciuk, M., Kruczkowska, W., Gałęziewska, J., Wanke, K., Kałuzińska-Kołat, Ż., Aleksandrowicz, M., & Kontek, R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252211955 · Cited by 98 · see citing works

Preserving Lysosomal Function in the Aging Brain: Insights from Neurodegeneration

Peng, W., Minakaki, G., Nguyen, M., & Krainc, D. (2019) · Neurotherapeutics · doi:10.1007/s13311-019-00742-3 · Cited by 79 · see citing works

Anti-inflammatory and Immune Therapy for Alzheimers Disease: Current Status and Future Directions

Walker, D., & Lue, L.-F. (2007) · Current Neuropharmacology · doi:10.2174/157015907782793667 · Cited by 66 · see citing works

Pharmacotherapeutic combinations for the treatment of Alzheimer’s disease.

Nagata, T., Shinagawa, S., Nakajima, S., Noda, Y., & Mimura, M. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2042514 · Cited by 11 · see citing works

New biologicals and biomaterials in the therapy of Alzheimer's disease

Prajapati, V., Shinde, S., Shrivastav, P., & Prajapati, B. G. (2024) · Alzheimer's Disease and Advanced Drug Delivery Strategies · doi:10.1016/b978-0-443-13205-6.00016-9 · Cited by 7 · see citing works

Perbandingan Efektivitas Penggunaan Donepezil dan Memantine Terhadap Perbaikan Fungsi Kognitif pada Penyakit Alzheimer

Alamri, K. N. H., Posangi, J., & Nangoy, E. (2021) · Jurnal Biomedik JBM · doi:10.35790/jbm.13.2.2021.31950 · Cited by 2 · see citing works

A comparative study of Memantine and Donepezil on the treatment of Alzheimer′s disease

Na, W. (2011) · Strait Pharmaceutical Journal · Cited by 1 · see citing works

An evaluation of memantine ER + donepezil for the treatment of Alzheimer’s disease

Calhoun, A. J., King, C., Khoury, R., & Grossberg, G. T. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1519022 · Cited by 61 · see citing works

P4‐334: Combination of memantine and donepezil reverses cognitive deficits in transgenic mice with both amyloid‐beta plaques and neurofibrillary tangles

LaFerla, F. M., Martínez‐Coria, H., Green, K. N., et al. (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.07.113 · Cited by 7 · see citing works

Strategies for managing patients with moderate to severe Alzheimer’s disease: high‐dose donepezil vs. memantine combination

Shim, Y., & Jung, S. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.073156 · Cited by 1 · see citing works